Evidentic’s therapeutic molecules, reference drugs and therapeutic antibodies are obtained from reference products and biosimilars. Reference products are referred as reference medicinal products (RMP) in Europe or reference listed drugs (RLD) in the USA. A product has established itself as a reference product if it was the first therapeutic agent to be approved in the market via a new approval (IND) and if it enjoys patent protection for a number of years. These products later serve generic companies to use these original products as reference substances for comparative analytical investigations and as comparator drugs in clinical studies. Especially for the biotechnology industry and the biosimilar industry, RMPs serve as the most important reference source for the active pharmaceutical ingredient (API) contained in them.